4 recruiting, 3 terminated, 1 completed, 1 not yet recruiting. 5 Phase 3, 3 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 3, Completed 1, Recruiting 1 |
| Phase 4 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Vaso-Occlusive Pain Episode in Sickle Cell Disease: new trials by email Literature Review of Vaso-Occlusive Pain Episode in Sickle Cell Disease trials Research Report on Vaso-Occlusive Pain Episode in Sickle Cell Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 2 | Recruiting | Mohsen Saidinejad | 120 | 2026-09-10 | 2026-09-02 |
| Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm) - Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD) | Phase 4 | Not yet recruiting | University of Mississippi Medical Center | 400 | 2026-08-01 | 2026-07-06 |
| Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Recruiting | Nantes University Hospital | 104 | 2026-07-03 | 2026-09-09 |
| Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease Depot medroxyprogesterone acetate (DMPA) - Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 4 | Recruiting | University of Pennsylvania | 65 | 2025-06-26 | 2026-05-28 |
| Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Not applicable | Recruiting | University of Maryland, Baltimore | 30 | 2024-11-01 | 2025-12-24 |
| Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient Clonidine - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 4 | Unknown | Centre Hospitalier Universitaire Saint Pierre | 40 | 2023-04-25 | 2023-05-08 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 242 | 2022-03-29 | 2025-12-17 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 72 | 2021-12-09 | 2024-12-11 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Completed | Pfizer | 241 | 2021-10-04 | 2025-12-02 |
| Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED Intranasal ketamine - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Terminated | Abigail Nixon | 5 | 2019-12-19 | 2024-11-18 |
Anemia, Sickle Cell (10) · Vaso-Occlusive Crises (6) · Agnosia (3) · Hematologic Diseases (3) · Sickle Cell Trait (2) · Acute Chest Syndrome (1) · Acute Pain (1)
Anemia (10) · Anemia, Hemolytic (10) · Anemia, Hemolytic, Congenital (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Hemic and Lymphatic Diseases (10) · Hemoglobinopathies (10) · Hematologic Diseases (7) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Perceptual Disorders (3) · Lung Diseases (1)
inclacumab (3) · Standard of Care (2) · Clonidine (1) · Health Services Needs and Demand (1)
Pfizer (3) · Abigail Nixon (1) · Centre Hospitalier Universitaire Saint Pierre (1) · Mohsen Saidinejad (1) · Nantes University Hospital (1) · University of Maryland, Baltimore (1) · University of Mississippi Medical Center (1) · University of Pennsylvania (1)
United States (8) · Brazil (3) · Colombia (3) · France (3) · Kenya (3) · Lebanon (3) · Nigeria (3) · Oman (3) · Saudi Arabia (3) · Turkey (Türkiye) (3) · Tanzania (2) · Belgium (1) · Egypt (1) · Germany (1) · Guadeloupe (1)
Andrea Roe, MD MPH (1) · John N Freeman, MD (1) · R. Gentry Wilklerson, MD (1)
2019 (1), R01HL175726 (1)